Close Menu

Lung Cancer

News and reporting on lung cancer.

Preparing for commercialization of its LungExpress Dx test, the company boosted R&D spending and trimmed general costs.

Source BioScience will provide a lung cancer companion diagnostic service for mutations linked to tyrosine kinase-based treatments.

NCI and NHLBI plan to give $12 million each for research into molecular, genetic, and other connections between the two diseases.

Through the formation of the Asian Cancer Research Group, Eli Lily, Merck, and Pfizer have also committed "to create one of the most extensive pharmacogenomic cancer databases known to date."

Med BioGene said that it will use the proceeds from the IPO to complete the validation of its first test, called LungExpress Dx, on a real-time, quantitative reverse transcriptase PCR platform. The test was initially developed on the Affymetrix GeneChip platform.

Genetic Technologies will distribute the ResponseDX tests in Australia and in five SE Asian Nations.

The Berlin-based firm trimmed its loss on higher sales from collaborations, licenses, and partnerships.

The company said it has signed a term sheet for an option to license patent applications related to knocking down beta III-tubulin using RNAi, an approach that has been shown to sensitize cancer cells to chemotherapy.

Based on a small, preliminary study, an NHGRI-led team concluded that smokers respond quite well to genetic test results provided online — a finding that could have implications for helping smokers kick the habit.

The technology "has broad potential uses in the development of cancer prognostic assays including response predictions to therapeutics as well as research tools and reagents," PrognosDx said in a statement.

Pages

In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.